Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT01622764 | 89Zr-RO5323441 PET Imaging in Glioblastoma | withdrawn | Phase 2 | 0 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 6, 2024 | clinicaltrials |
| NCT03035357 | Neoadjuvant Listeria or Daratumumab in Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 3, 2024 | clinicaltrials |
| NCT03044795 | Response to PARP Inhibitor Predicted by the RAD51 Assay(REPAIR) | withdrawn | Phase 2 | 0 | University Medical Center GroningenOTHER | 0 | May 3, 2024 | clinicaltrials |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer | withdrawn | Phase 2 | 0 | GenmabINDUSTRY | 6 | Apr 30, 2024 | clinicaltrials |
| NCT04614766 | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors(SPORE-3) | withdrawn | Phase 1 / Phase 2 | 0 | David BushnellOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | withdrawn | Phase 1 / Phase 2 | 0 | Indiana UniversityOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05900648 | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06331585 | Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy | withdrawn | Phase 2 | 0 | Hetian District People's HospitalOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05367401 | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 11, 2024 | clinicaltrials |
| NCT05465876 | Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL(PACE-CLL) | withdrawn | Phase 2 | 0 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05033132 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | Agenus Inc.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer(ANAPLAST-NEO) | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT05705466 | Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Kartos Therapeutics, Inc.INDUSTRY | 0 | Mar 22, 2024 | clinicaltrials |
| NCT04243941 | PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Mar 21, 2024 | clinicaltrials |
| NCT05967286 | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Mar 20, 2024 | clinicaltrials |
| NCT03098355 | Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Zhujiang HospitalOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05574712 | A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Mar 18, 2024 | clinicaltrials |
| NCT05613348 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma(CAR19T2) | withdrawn | Phase 1 / Phase 2 | 0 | Zhujiang HospitalOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03841747 | Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer(PELICAN) | withdrawn | Phase 2 | 0 | Queen Mary University of LondonOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT03982992 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab(DLI-TARGET) | withdrawn | Phase 2 | 0 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04102436 | Non-Viral TCR Gene Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05689359 | Evaluation of Hydroxychloroquine to Prevent CIPN | withdrawn | Phase 2 | 0 | University of ArizonaOTHER | 0 | Mar 8, 2024 | clinicaltrials |
| NCT05034562 | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT06085638 | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT04199520 | Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients | withdrawn | Phase 2 | 0 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06052423 | ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Mar 4, 2024 | clinicaltrials |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03190239 | Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients(XQonc-007) | withdrawn | Phase 2 | 0 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05703555 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701(INTRUSION) | withdrawn | Phase 2 | 0 | Erasmus Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04845035 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT06018116 | A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.(CANUCK-01) | withdrawn | Phase 2 | 0 | CHU de Quebec-Universite LavalOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT05829434 | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS(MAGROLIC) | withdrawn | Phase 2 | 0 | Uwe PlatzbeckerOTHER | 0 | Feb 12, 2024 | clinicaltrials |
| NCT04242329 | Surgery of Melanoma Metastases After Systemic Therapy(SUMMIST) | withdrawn | Phase 2 | 0 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT05331131 | Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial | withdrawn | Phase 2 | 0 | Northwell HealthOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05315687 | Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT05724849 | Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | Vanderbilt University Medical CenterOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 12, 2024 | clinicaltrials |
| NCT03135652 | Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation | withdrawn | Phase 2 | 0 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT03193814 | Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer(XHZL) | withdrawn | Phase 2 | 0 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT00979693 | Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma | withdrawn | Phase 2 | 0 | Multidisciplinary Association for Psychedelic StudiesOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06180863 | Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02531854 | A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy | withdrawn | Phase 2 | 0 | Advaxis, Inc.INDUSTRY | 0 | Dec 19, 2023 | clinicaltrials |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy(CheckMate 79X) | withdrawn | Phase 1 / Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 19, 2023 | clinicaltrials |
| NCT05948462 | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib(NSCLC) | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 17, 2024source: clinicaltrials